Christopher Durant Turner - 26 Jul 2023 Form 4 Insider Report for Nuvalent, Inc. (NUVL)

Role: Chief Medical Officer
Signature: /s/ Deborah Ann Miller, attorney-in-fact
Issuer symbol: NUVL
Transactions as of: 26 Jul 2023
Net transactions value: -$206,542
Form type: 4
Filing time: 28 Jul 2023, 16:51:58 UTC
Previous filing: 24 Jul 2023
Next filing: 06 Oct 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NUVL	Class A Common Stock	Options Exercise	$16,295	+2,365	+16%	$6.89^*	16,878	26 Jul 2023	Direct	F1
transaction	NUVL	Class A Common Stock	Sale	$110,800	-2,365	-14%	$46.85	14,513	26 Jul 2023	Direct	F1, F2
transaction	NUVL	Class A Common Stock	Options Exercise	$18,362	+2,665	+18%	$6.89^*	17,178	28 Jul 2023	Direct	F1
transaction	NUVL	Class A Common Stock	Sale	$130,398	-2,665	-16%	$48.93	14,513	28 Jul 2023	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NUVL	Stock Option (Right to Buy)	Options Exercise	$0	-2,365	-0.75%	$0.000000	313,765	26 Jul 2023	Class A Common Stock	2,365	$6.89	Direct	F1, F4
transaction	NUVL	Stock Option (Right to Buy)	Options Exercise	$0	-2,665	-0.85%	$0.000000	311,100	28 Jul 2023	Class A Common Stock	2,665	$6.89	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 21, 2021.
F2	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.80 to $46.98, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.
F3	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.86 to $49.04, inclusive.
F4	The shares underlying this option vest as follows: 25% of the shares vested on March 22, 2022, and the remainder have vested or shall vest over the next three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.